Tivic completes verification of entolimod™ cell line: first step in establishing cgmp manufacturing for bla filing

Fremont, calif.--(business wire)--tivic health® systems, inc. (nasdaq: tivc), a diversified immunotherapeutics company, today announced that it has completed verification of its entolimod™ cell line, the first step in establishing current good manufacturing practices (cgmp) in preparation for a biologics license application, or bla. cell line verification in recombinant protein production is required because it ensures the processes used to grow cells and activate protein expression do not comp.
TIVC Ratings Summary
TIVC Quant Ranking